JP Morgan Targets Weight Loss Drugs With $500M Fund The current duopoly in the GLP-1 game figures to be short-lived as more investors enter the space, experts say JP Morgan Private Capital, a venture capital and growth equity investment team under JP Morgan Asset Management, has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space
I highly recommend this place for all your med spa needs
GLP-1 medications work in direct opposition to this by signaling fullness to the brain
Lean Mass Loss: Without a high-protein routine, users risk losing significant muscle alongside fat, which can impact long-term strength
Today and beyond Learn how GLP-1s can help with more than weight loss People with heart disease had 20% fewer heart attacks, strokes, or heart-disease related deaths
Notably, oral semaglutide has compared favorably when studied head-to-head against a variety of agents, including an SGLT-2 inhibitor and injectable liraglutide